On January 22, 2020 Phesi, a data-driven provider of premier integrated clinical development analytics products and services, reported that OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS) has purchased a multi-year ClinSite license to enable more accurate and precise planning for Phase 2 and 3 clinical trials of anticancer immunotherapies developed with OncoSec’s plasmid DNA delivery platform (Press release, OncoSec Medical, JAN 22, 2020, View Source [SID1234553419]). ClinSite is a self-service, artificial intelligence (AI)-powered tool that allows biopharmaceutical companies to search for and select top-performing investigator sites for clinical trials in all therapeutic areas.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"As a ClinSite licencee, OncoSec can utilize this novel tool to select the right investigator sites for their immune-oncology clinical trials across a range of tumor types," said Gen Li, PhD, MBA, Phesi founder and president. "Many drug studies fail or are unnecessarily prolonged due to the lack of timely and precise data to inform trial protocols and investigator site selection. With our AI-driven predictive analytics and insights, Phesi’s tools generate accurate, real-time data, allowing companies such as OncoSec to accelerate their trial timelines and enhance their efficiency."
"Access to Phesi’s innovative technology will be a boon to OncoSec’s clinical development programs, particularly our later-stage trials in advanced melanoma, head and neck cancer, and triple-negative breast cancer," noted Kellie Malloy Foerter, chief clinical development officer at OncoSec. "Despite the relatively small patient populations affected by these malignancies, the array of unmet medical needs, combined with the sheer number of ongoing and planned clinical trials in these indications, presents a complex landscape for patients, investigators, and trial sponsors to negotiate. We are therefore excited to deploy ClinSite to optimize our clinical development planning processes, and are eager to see the results as Phesi’s ClinSite reporting capabilities evolve."